Samsung BioLogics shares rise after agrees to make Moderna COVID-19 vaccine By Reuters

<iframe src=”//″ width=”250″ height=”250″ scrolling=”no” border=”0″ marginwidth=”0″ style=”border:none;” frameborder=”0″></iframe>

© Reuters. FILE PHOTO: A vial containing the Moderna COVID-19 vaccine is seen at a temporary vaccination center of Swiss Medix health center as the spread of the coronavirus disease continues, in the Offene St. Jakob Kirche Reformed church in Zurich, Switzerland May

SEOUL (Reuters) – Shares in South Korean drug contract manufacturer Samsung (KS:) BioLogics rose as much as 5.2% in early Monday trade, after it agreed to fill-finish manufacture Moderna (NASDAQ:)’s COVID-19 vaccine.

The agreement was part of Moderna Inc and Novavax (NASDAQ:) Inc entering into a deal with the South Korean government to manufacture their COVID-19 vaccines.

The wider market was down 0.2% as of 0007 GMT.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


86 − 78 =